Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Marshall SF, Burghaus R, Cosson V, Cheung SY, Chenel M, DellaPasqua O, et al. Good practices in model-informed drug discovery and development: practice, application, and documentation. CPT Pharmacometrics Syst Pharmacol. 2016;5(3):93–122.
2. Food and Drug Administration (FDA). Guidance for industry: population pharmacokinetics 1999 [Available from:
https://www.fda.gov/downloads/drugs/guidances/UCM072137.pdf
. Accessed 15 April 2019.
3. European Medicines Agency (EMA). Guideline on reporting the results of population pharmacokinetic analyses 2007 [Available from:
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003067.pdf
. Accessed 15 April 2019.
4. Manolis E, Brogren J, Cole S, Hay JL, Nordmark A, Karlsson KE, et al. Commentary on the MID3 good practices paper. CPT Pharmacometrics Syst Pharmacol. 2017;6(7):416–7.
5. Byon W, Smith MK, Chan P, Tortorici MA, Riley S, Dai H, et al. Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacometrics Syst Pharmacol. 2013;2:e51.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献